SCHEMBL1720554

SCHEMBL1720554

CCN(CC)Cc1c(C)[nH]c(=O)c2cc(F)ccc12

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MPO P05164 3/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 1/20 0.44
PGR P06401 1/20 0.39
AR P10275 1/20 0.39
TSHR P16473 1/20 0.39
PARP1 P09874 6/20 0.38
GFER P55789 1/20 0.38
HTR1A P08908 1/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
ICMT O60725 3/20 0.36
PARP3 Q9Y6F1 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719760 0.87 CYP3A4 (0.44) MPOKDM4EALDH1A1HPGDHSD17B10
SCHEMBL1720536 0.83 PARP1 (0.45) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL1720615 0.82 PARP1 (0.39) KDM4EPGRARPARP1KEAP1
SCHEMBL1719757 0.81 TSHR (0.52) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL1720998 0.77 PARP1 (0.42) PGRARPARP1KEAP1NFE2L2
Iodide SCHEMBL1721148 0.76 PARP1 (0.41) PGRARPARP1KEAP1NFE2L2
SCHEMBL1720050 0.75 PARP1 (0.38) MPOKDM4EALDH1A1HPGDHSD17B10
SCHEMBL30720811 0.74 PGR (0.47) KDM4EALDH1A1PGRARPARP1
SCHEMBL10227704 0.73 PARP1 (0.43) MPOKDM4EPGRARPARP1
SCHEMBL1721010 0.73 KMT2A (0.48) MPOKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 MPO 26/4885KDM4E 3585/4885ALDH1A1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.